The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Resistance mechanisms following first-line lorlatinib: insights from the CROWN trial
Tony Mok, MD, Chinese University of Hong Kong, Hong Kong, China, discusses that in the Phase III CROWN study (NCT03052608), following first-line lorlatinib, no L-dependent resistance mechanisms were observed, however they identified RAS pathway mutations and tumor suppressor genes. Prof. Mok highlights that these findings do not provide sufficient evidence to inform treatment choices for patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
